ChemoMetec Reports Q1 Revenue Growth and DKK 100.3M EBITDA
Revenue in ChemoMetec’s core LCB business rose 31% year over year in Q1 2026/27, accounting for 96% of total revenue. EBITDA was DKK 100.3 million, with a 63% margin versus 55% a year earlier. The company maintained its previously announced full-year guidance.
ChemoMetec reported that revenue in its core LCB business area increased by 31% during the first quarter of the 2026/27 financial year compared to the same period last year. The LCB segment accounted for 96% of total revenue for the quarter. EBITDA for the period reached DKK 100.3 million, resulting in an EBITDA margin of 63%, up from 55% in the year-earlier period. The company maintained its previously announced full-year revenue and EBITDA guidance for 2026/27, which was most recently upgraded on November 3, 2026.